Abbvie Inc.

E.i. Dupont De Nemours and Company

Steven Lewis Swann, Jr

Helmut Mack

Anil Vasudevan

Adrian Hobson

Nicole Teusch

Thomas Dale Penning

Stevan Wakefield Djuric

Sean Colm Turner

Julie M Miyashiro

Alan Frank Gasiecki

Keith W Woods

Jyoti R Patel

Qi Shuai

Irini Akritopoulou-Zanze

Kathy A Sarris

Douglas M Kalvin

Biqin C Li

Lu Wang

Dawn M George

Brian D Wakefield

Melissa J Michmerhuizen

Vijaya J Gracias

Andrew J Long

Eric F Johnson

Peter J Kovar

Wilfried Hornberger

Andrew Edmund Taggi

Jeffrey Keith Long

Stephen Frederick McCann

Chi-Ping Tseng

Daryl Richard Sauer

Ryan G Keddy

Paula Louise Sharpe

Dominique Bonafoux

Margaretha Bakker

Michael F Jarvis

N St John Moore

Margaretha H M Bakker

Nigel S Moore

Bernhard K Muller

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R, R, Rand m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

5-substituted indazoles as kinase inhibitors

The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). Rand Rare, independently of each other, hydrogen, hydroxy, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy or C-C-haloalkoxy; R, R, Rand Rare, independently of each other, hydrogen, hydroxy, halogen, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy, C-C-haloalkoxy, amino, C-C-alkylamino or di-(C-C-alkyl)-amino; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, aryl or aryl-C-C-alkyl; Ris a group of the formula &#x2014;X&#x2014;W, where X is a single bond, C-C-alkylene or C-C-alkylene-O&#x2014;, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; Ris a group of the formula &#x2014;Y&#x2014;Z, where Z is hydrogen, halogen, OR, NRR, S(O)&#x2014;R, phenyl which may carry 1, 2, 3 or 4 substituents Ror a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched CC-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond. 

4-(4-pyridinyl)-benzamides and their use as rock activity modulators

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Substituted benzene fungicides

Growing community of inventors

San Diego, CA, United States of America

Steven Lewis Swann, Jr